A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dato-DXd|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Eribulin|DRUG: Vinorelbine
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo